



Clinical Trial Information Sheet

Puma Biotechnology is committed to patients and care partners having the information you need to make informed decisions with your healthcare provider about your treatment options.

ABOUT THIS CLINICAL TRIAL

The ALISCA-Lung1 is a Phase 2 clinical trial of alisertib alone for the treatment of patients with small cell lung cancer (SCLC).

WHO IS ELIGIBLE?

The ALISCA-Lung1 clinical trial is open to patients 18 years or older with pathologically confirmed SCLC following progression on or after treatment with one platinum-based chemotherapy and immunotherapy. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. Talk to your doctor to discuss your eligibility.

WHAT'S INVOLVED?

- A screening period (to do some tests and procedures to confirm eligibility)
- A treatment period (total length depends on each patient)
- An end-of-treatment visit (when the patient stops taking alisertib)
- A safety follow-up visit (28 days after the last dose of alisertib)
- A long-term follow-up period
- Total length of participation in the clinical trial is approximately 14 months

WHO IS SPONSORING THIS CLINICAL TRIAL?

This trial is sponsored by Puma Biotechnology, a biopharmaceutical company focused on developing treatment options for different types of cancer.



*The ALISCA-Lung1
alisertib trial is OPEN
for enrollment!*

For more information on the clinical trial, location of trial sites, and how to enroll,

- go to: <https://clinicaltrials.gov/study/NCT06095505> or
- email: clinicaltrials@pumabiotechnology.com

For more information on the trial Sponsor,

- go to: <https://pumabiotechnology.com>